

Peter Foley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/426706/publications.pdf>

Version: 2024-02-01

52
papers

3,847
citations

218677

26
h-index

254184

43
g-index

52
all docs

52
docs citations

52
times ranked

3549
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	13.7	884
2	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 418-431.	1.2	554
3	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	13.7	457
4	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018, 379, 1313-1321.	27.0	301
5	Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2466-2469.	0.7	131
6	The frequency of reactions to sunscreens: results of a longitudinal population-based study on the regular use of sunscreens in Australia. <i>British Journal of Dermatology</i> , 1993, 128, 512-518.	1.5	130
7	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1093-1102.	1.2	110
8	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. <i>JAMA Dermatology</i> , 2018, 154, 676.	4.1	90
9	Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. <i>International Journal of Dermatology</i> , 2009, 48, 1236-1245.	1.0	77
10	The Frequency of Common Skin Conditions in Preschool-aged Children in Australia. <i>Archives of Dermatology</i> , 2003, 139, 318-22.	1.4	71
11	Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 477-482.	2.4	71
12	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	1.2	71
13	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2437-2446.e1.	0.7	70
14	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1562-1574.	1.5	68
15	Psoriasis in those planning a family, pregnant or breastfeeding. The Australasian Psoriasis Collaboration. <i>Australasian Journal of Dermatology</i> , 2018, 59, 86-100.	0.7	67
16	Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1940-1949.	2.4	62
17	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2018, 178, 132-139.	1.5	57
18	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2830-2838.	2.4	46

#	ARTICLE	IF	CITATIONS
19	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00402.	1.3	45
20	The frequency of common skin conditions in preschool-age children in Australia: atopic dermatitis. <i>Archives of Dermatology</i> , 2001, 137, 293-300.	1.4	43
21	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	3.0	40
22	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 155-164.	6.7	37
23	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.5	36
24	Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study. <i>Journal of Sexual Medicine</i> , 2018, 15, 1645-1652.	0.6	34
25	Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDT. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 3S-16S.	1.2	33
26	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	3.0	30
27	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase <scp>III</scp> randomized, controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 498-506.	2.4	28
28	Current and Future Oral Systemic Therapies for Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 91-109.	1.7	26
29	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	6.7	24
30	Physician perceptions and experience of current treatment in actinic keratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 298-306.	2.4	23
31	Psoriasis and cancer. An Australian/New Zealand narrative. <i>Australasian Journal of Dermatology</i> , 2019, 60, 12-18.	0.7	21
32	A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. <i>Journal of Drugs in Dermatology</i> , 2011, 10, 1432-8.	0.8	21
33	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1357-1372.	3.0	19
34	Current landscape for treatment of advanced basal cell carcinoma. <i>Australasian Journal of Dermatology</i> , 2015, 56, 1-7.	0.7	14
35	Adherence to topical therapies in actinic keratosis: A literature review. <i>Journal of Dermatological Treatment</i> , 2016, 27, 538-545.	2.2	14
36	Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative. <i>Australasian Journal of Dermatology</i> , 2020, 61, 9-22.	0.7	12

#	ARTICLE	IF	CITATIONS
37	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	2.2	10
38	Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. <i>Australasian Journal of Dermatology</i> , 2005, 46, S8-S10.	0.7	5
39	Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. <i>Australasian Journal of Dermatology</i> , 2005, 46, S8-S10.	0.7	4
40	Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (<scp>SUSTAIN</scp> study). <i>Australasian Journal of Dermatology</i> , 2022, 63, 303-311.	0.7	4
41	Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry. <i>Australasian Journal of Dermatology</i> , 2020, 61, 380-382.	0.7	3
42	Dermatologist attitudes toward ciclosporin use in atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-3.	2.2	2
43	Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital. <i>Dermatologic Therapy</i> , 2021, 34, e15128.	1.7	2
44	Practical aspects of methyl aminolaevulinate photodynamic therapy. <i>Australasian Journal of Dermatology</i> , 2005, 46, S12-S13.	0.7	0
45	Methyl aminolaevulinate photodynamic therapy in practice: Treatment protocol. <i>Australasian Journal of Dermatology</i> , 2005, 46, S14-S14.	0.7	0
46	Methyl aminolaevulinate photodynamic therapy in practice: Treatment protocol. <i>Australasian Journal of Dermatology</i> , 2005, 46, S14.	0.7	0
47	Practical aspects of methyl aminolaevulinate photodynamic therapy. <i>Australasian Journal of Dermatology</i> , 2005, 46, S12-S13.	0.7	0
48	Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program. <i>International Journal of Dermatology</i> , 2009, 48, 1376-1384.	1.0	0
49	FRI0435...INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL. , 2019, , .		0
50	POS1031...LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 787-788.	0.9	0
51	Practical aspects of methyl aminolaevulinate photodynamic therapy. <i>Australasian Journal of Dermatology</i> , 2005, 46 Suppl 3, S12-3; discussion S23-5.	0.7	0
52	Methyl aminolaevulinate photodynamic therapy in practice: treatment protocol. <i>Australasian Journal of Dermatology</i> , 2005, 46 Suppl 3, S14; discussion S23-5.	0.7	0